Combination strategies for pain management

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 10, 2003, Pages 1697-1708

  Raffa, Robert B ^a   Clark Vetri, Rachel ^a   Tallarida, Ronald J ^b   Wertheimer, Albert I ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesics; Combinations; Pain management; Synergy

Indexed keywords

'CAPITAL'; 4 AMINOBUTYRIC ACID; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CALCITONIN; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DICLOFENAC; DIFLUNISAL; FENOPROFEN; HYDROCODONE BITARTRATE PLUS IBUPROFEN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORCO; OPIATE DERIVATIVE; OXAPROZIN; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PERCOCET; PERCODAN; PROPACET; ROXICET; SULINDAC; TOLMETIN; TRAMADOL; TYLOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZYDONE;

ADDICTION; CLINICAL PRACTICE; CONSTIPATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER TOXICITY; METHODOLOGY; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PSYCHOGENIC PAIN; REVIEW; VISCERAL PAIN;

ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOTHERAPY, ADJUVANT; DRUG COSTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; PAIN; PAIN MEASUREMENT;

EID: 0142210237     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.10.1697     Document Type: Review

References (38)

1. BRANDT KD: Safety issues relevant to NSAIDs and COX-2-selective agents (Coxibs) and evaluation of patient satisfaction with drug therapy for OA. J. Clin. Rheumatol. (2003) 9(Suppl.):S7-S12.
2. WOOLF CJ: Windup and central sensitization are not equivalent. Pain (1996) 66:105-108.
3. KATZ WA, BJORKMAN DJ, FENDRICK AM et al.: Challenges and progress in managing chronic pain. Analgesia (2000) 4:483-504.
4. RAFFA R: Pharmacology of oral combination analgesics: rational therapy for pain. J. Clin. Pharm. Thera. (2001) 26:257-264.
5. SUTHERLAND SP, COOK SP, MCCLESKEY EW: Chemical mediators of pain due to tissue damage and ischemia. Prog. Brain Res. (2000) 129:21-38.
6. FIELDS HL: Pain. McGraw-Hill, New York (1987):13-40.
7. WERTHEIMER AI, MORRISON A: Combination drugs: innovation in pharmacotherapy. Pharm. Ther. (2002) 27:44-49.
8. HAYNES RB: A critical review of the 'determinants' of patient compliance with therapeutic regimens. In: Compliance with therapeutic regimens. Sackett DL, Haynes RD (Eds), Johns Hopkins University, Baltimore, USA (1976):26-39.
9. TALLARIDA RJ, STONE DJ Jr, RAFFA RB: Efficient designs for studying synergistic drug combinations. Life Sci. (1997) 61:417-425.
10. TALLARIDA RJ: Statistical analysis of drug combinations for synergism. Pain (1992) 49:93-97.
11. ANONYMOUS: Acetaminophen safety. Medical Lett. (2002) 44:91-93.
12. MERCADANTE S, PORTENOY RK: Opioid poorly responsiveness cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J. Pain Sympt. Manage. (2002) 21:338-54.
13. MCCAFFREY M, PASERO C, PAICE JA: Basic mechanisms underlying the causes and effects of pain. In: Pain; Clinical Manual (2nd edn). McCaffrey M, Pasero C (Eds), Mosley, New York, USA (1999):15-31.
14. MERCADANTE S, PORTENOY RK: Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J. Pain Sympt. Manag. (2001) 21:144-150.
15. LIPMAN AG: Internal analgesic and antipyretic products. In: Handbook of Nonprescription Drugs. American Pharmaceutical Association, Washington DC, USA (1996):45-74.
16. ROWBOTHAM DJ: COX-2 selective inhibitors: clinical relevance in surgical and acute pain. Eur. J. Anesthesiol. (2002) 19(Suppl. 25):11-20.
17. RASMUSSEN GL, STECKNER K, HOGUE C et al.: Intravenous parecoxib sodium for acute pain after postorthopedic knee surgery. Am. J. Orthop. (2002) 31:334-343.
18. BARTON SF, LANGELAND FF, SNAPES MC et al.: Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following orthopedic surgery. Anesthesiol. (2002) 97:306-314.
19. DANIELSS, KUSS M, MEHLISCH D et al.: Pharmacokinetic and efficacy evaluation of intravenous parecoxib in a postsurgical dental pain model. Gastroenterol. (2000) 67:PIII (Abstract PIII-8).
20. MCCAFFREY M, PORTENOY RK: Nonopioids acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs). In: Pain; Clinical Manual (2nd edn). McCaffrey M, Pasero C (Eds), Mosley, New York, USA (1999):130-152.
21. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340:1888-1899.
22. BOMBARRDIER C, LAINE I, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis (VIGOR study). N. Engl. J. Med. (2000) 343:1520-1528.
23. DEMARIA AN, WEIR MR: Coxibs-Beyond the GI tract: renal and cardiovascular issues. J. Pain Sympt. Manage. (2003) 25:S41-S49.
24. PORTENOY RK, MCCAFFREY M: Ajuvant analgesics. In: Pain; Clinical Manual (2nd edn), McCaffrey M, Pasero C (Eds). Mosley, New York, USA (1999):303-340.
25. ANONYMOUS: Drugs for Pain. Drugs of Choice from the Medical Letter (14th edn). The Medical Letter, New Rochelle, NY, USA (2001):138-150.
26. BOLAN EA, TALLARIDA RJ, PASTERNAK GW: Synergy between mu receptor subtypes: evidence for functional interaction among mu receptor subtypes. J. Pharmacol. Exp. Ther. (2002) 303:557-562.
27. OSSIPOV MH, HARRIS S, LLOYD P, MESSINEO E: An isobolographic analysis of the antinociceptive effect of systemically and intrathecally administered combinations of clonidine and opiates. J. Pharmacol. Exp. Ther. (1990) 255:1107-1116.
28. TALLARIDA RJ, STONE DJ Jr, MCCARY JD, RAFFA RB: A response surface analysis of synergism between morphine and clonidine. J. Pharmacol. Exp. Ther. (1990) 289:8-13.
29. TALLARIDA RJ, COWAN A, RAFFA RB: Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J. Pharmacol. Exp. Ther. (In Press).
30. 1 antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J. Pharmacol. Exp. Ther. (2002) 303:730-735.
31. 5-enkephalin in morphine-tolerant and nontolerant mice. J. Pharmacol. Exp. Ther. (1991) 257:1091-1099.
32. RAFFA RB, STONE DJ Jr, TALLARIDA RJ: Discovery of self-synergistic spinal/supraspinal antinociception produced by acetaminophen (paracetamol). J. Pharmacol. Exp. Ther. (2000) 295:291-294.
33. GEBHART GF: Comments on the isobole method for analysis of drug interactions. Pain (1992) 51:381; Author reply: 383-388.
34. TALLARIDA RJ: Drug Synergism and Dose-Effect Data Analysis. Chapman & Hall/CRC Press, Boca Raton (2000).
35. FAIRBANKS CA, WILCOX GL: Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J. Pharmacol. Exp. Ther. (1999) 288:1107-1116.
36. OTSUKA M, YOSHIOKA K: Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. (1993) 73:229-308.
37. RAFFA RB, FRIDERICHS E, REIMANN W et al.: Complementary and synergistic antinociceptive interactions between the enantiomers of tramadol. J. Pharmacol. Exp. Ther. (1993) 267:331-340.
38. JOHNSON JA, BOOTMAN JL: Drug related morbidity and mortality: a cost of illness model. Arch. Intern. Med. (1995) 155:1949-1956.